Prothena Q1 net loss $60.2M, cash $418.8M; AFFIRM-AL data due Q2 2025

PROTHENA CORP PUBLIC LTD CO

2025-Q1 EPS reported -$1.12 revenue$2,828,000

Net loss $60.2M ($1.12/share) vs $72.2M ($1.34/share) year ago; revenue $2.8M (from BMS collaboration).
Cash $418.8M at quarter end; FY2025 net cash burn guidance $168-175M, ending cash ~$301M.
Phase 3 AFFIRM-AL (birtamimab) topline results expected Q2 2025; SPA with FDA, primary endpoint all-cause mortality.
Multiple PRX012 Phase 1 readouts expected from mid-2025; Roche to decide prasinezumab next steps mid-year.
Novo Nordisk's coramitug Phase 2 for ATTR-CM completes enrollment; results expected H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.